Clinical Trial

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-07; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-09-29
Trial Details
NCT Number NCT06927999
Lead Sponsor ARS Pharmaceuticals, Inc.
Conditions Urticaria Chronic
Enrollment 42 participants
Start Date 2025-07-09
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-22